Malignant Neoplasm of Unknown Primary

subtype

Identifier: CI-CAN-00001150
Entity page: /cancer/malignant-neoplasm-of-unknown-primary ↗
Edges: 9,401

Neighbours: 15 genes21 drugs10 trials
Drawn: 46 of 46 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Malignant Neoplasm of Unknown Primary approved for …APPROVED_FORderived15 of 57show all (up to 200)
← approved for	Fluorouracilsmall molecule FDA (US) · approved · 2026-02-20 · Adenocarcinoma of the Breast	—	approved	Breast Adenocarcinoma	1	Regulatory	openfda	graph →
← approved for

Malignant Neoplasm of Unknown Primary altered in cohorts of …ALTERED_INderived15 of 1,064show all (up to 200)
← altered in cohorts of	COL7A1 450 / 536 cases (84 %) · ssm · TCGA-KIRC · largest of 2 cohorts	—	—	Clear Cell Renal Cell Carcinoma	2	Observed	gdc	graph →
← altered in cohorts of	GLB1 450 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	PLXNB1 450 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	ATRIP 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	CCDC51 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	CDC25A 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	CELSR3 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	FBXW12 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	HHATL 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	IP6K2 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	NCKIPSD 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	PFKFB4 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	PRKAR2A 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	PTH1R 449 / 536 cases (84 %) · ssm · TCGA-KIRC	—	—	Clear Cell Renal Cell Carcinoma	1	Observed	gdc	graph →
← altered in cohorts of	SCN5A 449 / 536 cases (84 %) · ssm · TCGA-KIRC · largest of 2 cohorts	—	—	Clear Cell Renal Cell Carcinoma	2	Observed	gdc	graph →

Malignant Neoplasm of Unknown Primary altered in cohorts of …ALTERED_INderived15 of 1,064show all (up to 200)

← altered in cohorts of

COL7A1

450 / 536 cases (84 %) · ssm · TCGA-KIRC · largest of 2 cohorts

—

Clear Cell Renal Cell Carcinoma

Observed

Malignant Neoplasm of Unknown Primary investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 326show all (up to 200)
→ investigated in trials for	Pembrolizumabmonoclonal antibody 347 trials (161 active) · roll-up of the cancer and its descendants	—	—	Malignant Neoplasm of Unknown Primary	347	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 269 trials (98 active) · roll-up of the cancer and its descendants	—	—	Malignant Neoplasm of Unknown Primary	269	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 222 trials (90 active) · roll-up of the cancer and its descendants	—	—	Malignant Neoplasm of Unknown Primary	222	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 218 trials (89 active) · roll-up of the cancer and its descendants	—	—	Malignant Neoplasm of Unknown Primary	218	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 190 trials (84 active) · roll-up of the cancer and its descendants	—	—	Malignant Neoplasm of Unknown Primary	190	Observed	clinicaltrials	graph →
→ investigated in trials for	Sorafenibsmall molecule 189 trials (14 active) · roll-up of the cancer and its descendants	—	—	Malignant Neoplasm of Unknown Primary	189	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall molecule 180 trials (68 active) · roll-up of the cancer and its descendants	—	—	Malignant Neoplasm of Unknown Primary	180	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 173 trials (48 active) · roll-up of the cancer and its descendants	—	—	Malignant Neoplasm of Unknown Primary	173	Observed	clinicaltrials	graph →
→ investigated in trials for	Fluorouracilsmall molecule 156 trials (41 active) · roll-up of the cancer and its descendants	—	—	Malignant Neoplasm of Unknown Primary	156	Observed	clinicaltrials	graph →
→ investigated in trials for	Lenvatinibsmall molecule 152 trials (66 active) · roll-up of the cancer and its descendants	—	—	Malignant Neoplasm of Unknown Primary	152	Observed	clinicaltrials	graph →
→ investigated in trials for	Cetuximabmonoclonal antibody 114 trials (28 active) · roll-up of the cancer and its descendants	—	—	Malignant Neoplasm of Unknown Primary	114	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 112 trials (33 active) · roll-up of the cancer and its descendants	—	—	Malignant Neoplasm of Unknown Primary	112	Observed	clinicaltrials	graph →
→ investigated in trials for	Durvalumabmonoclonal antibody 108 trials (54 active) · roll-up of the cancer and its descendants	—	—	Malignant Neoplasm of Unknown Primary	108	Observed	clinicaltrials	graph →
→ investigated in trials for	Nab-paclitaxel 107 trials (39 active) · roll-up of the cancer and its descendants	—	—	Malignant Neoplasm of Unknown Primary	107	Observed	clinicaltrials	graph →
→ investigated in trials for	Atezolizumabmonoclonal antibody 103 trials (60 active) · roll-up of the cancer and its descendants	—	—	Malignant Neoplasm of Unknown Primary	103	Observed	clinicaltrials	graph →

Malignant Neoplasm of Unknown Primary studied in …STUDIED_INderived10 of 7,954show all (up to 200)
→ studied in	NCT00423306Phase 2 · completed A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma · condition mapped ONTOLOGY_EXACT · 7,954 trials mapped (2,703 active)	—	—	Hepatocellular Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02345265Phase 2 · active not recruiting Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 7,954 trials mapped (2,703 active)	—	—	Fallopian Tube Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02446600Phase 3 · active not recruiting Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 7,954 trials mapped (2,703 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02502266Phase 2/Phase 3 · active not recruiting Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 7,954 trials mapped (2,703 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02743741NA · completed Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors · condition mapped ONTOLOGY_EXACT · 7,954 trials mapped (2,703 active)	—	—	Neuroendocrine Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT03348631Phase 2 · active not recruiting Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer · condition mapped CURATED_BROADER · 7,954 trials mapped (2,703 active)	—	—	Ovarian Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03598257Phase 2 · active not recruiting Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer · condition mapped ONTOLOGY_EXACT · 7,954 trials mapped (2,703 active)	—	—	Breast Inflammatory Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 7,954 trials mapped (2,703 active)	—	—	Collecting Duct Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03897543Phase 1/Phase 2 · completed ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma · condition mapped ALIAS · 7,954 trials mapped (2,703 active)	—	—	Hepatocellular Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04175912Phase 2 · active not recruiting Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver · condition mapped CURATED_BROADER · 7,954 trials mapped (2,703 active)	—	—	Hepatocellular Carcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains